Findings from a new study has shown that early response to ixekizumab and ustekinumab is associated with maintaining stable long-term skin clearance in patients with moderate-to-severe psoriasis.
Self-help interventions help reduce shame and improve QOL in psoriasis patients, study shows
According to a new study, some psoriasis patients may experience a reduction in shame and improvement in quality of life (QOL) after exposure to self-help interventions.
Researchers review HS biomarkers and criteria for validation in clinical trials
Researchers have reviewed the literature on biomarkers for hidradenitis suppurativa (HS) to evaluate the validity of these biomarkers and to identify the reasons for their lack of use in clinical trials.
Psoriasis patients experience vaccine hesitancy and treatment disruptions during pandemic
A new study evaluates vaccine hesitancy and medication changes in psoriasis patients during the Covid-19 pandemic.
Dupilumab reduces hospitalizations in patients with AD, according to new study
According to a new study, adult patients with moderate-to-severe atopic dermatitis (AD) being treated with dupilumab had lower rates of hospitalization and shorter stays when compared to those not on dupilumab.
New study shows association of atopic dermatitis with delinquent behaviours in youth
A recent meta-analysis has suggested a link between atopic dermatitis (AD) and delinquent behaviours in children and adolescents in the US.
New study shows Tapinarof cream reduces severity of plaque psoriasis
Tapinarof 1% cream was superior to vehicle control in reducing the severity of plaque psoriasis over a 12 week period, according to a new study.
Study shows higher doses of upadacitinib produce added benefit in moderate-to-severe AD
Higher doses of upadicitinib show added benefits for adults with moderate-to-severe atopic dermatitis (AD) when compared to dupilumab, according to a new study.
New study finds AD patients may be at greater risk of systemic and psychiatric comorbidities
According to a new study, adults with atopic dermatitis (AD) have a higher incidence of systemic, autoimmune, and psychiatric comorbidities than those without AD.
New study shows AD patients on dupilumab may experience less severe Covid-19 symptoms
Patients being treated with dupilumab for atopic dermatitis (AD) may experience less severe Covid-19 symptoms, according to a new study.
HealthMinute.TV 